Trial Profile
A retrospective study to evaluate the efficacy of Crizotinib and its association with different ROS1 fusion partners in Non-small cell lung cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jun 2017
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology